Explore original, structured summaries for research and education.
Research profile
B7-33(Relaxin)
B7-33(Relaxin) is indexed as a Single-chain peptide research entry. Its current evidence category is (Relaxin), and published discussion commonly places it within Healing & Recovery. This profile summarizes identifiers and literature signals; it does not provide treatment or dosing advice.
Identity
Molecular Data
- Molecular weight
- ~4,000 Da
- Chain length
- —
- Type
- Single-chain peptide
- Reported half-life
- Not well characterized
Single-chain analog of relaxin-2 B-chainLiterature map
Research indications
Cardiovascular
- Cardiac Fibrosiseffective
- Vasodilationeffective
- Heart Failuremoderate
Anti-Fibrotic
- Organ Fibrosiseffective
- Renal Fibrosismoderate
Evidence-gated guidance
Dosing Protocols
No established human dosing protocol is recognized for this research entry. Animal, laboratory, community, or vendor regimens must not be converted into personal dosing instructions.
- Dose
- Not established on this profile
- Frequency
- Not established on this profile
- Cycle
- Not established on this profile
- Storage
- Follow the exact supplier or authorized product documentation; requirements vary by formulation
Combination risks
Interactions
Evidence status
No independently verified interaction table is available here for B7-33(Relaxin). Interaction risk depends on identity, formulation, medicines, supplements, and health conditions.
Do not infer compatibility
Being listed beside another compound does not mean that combining them is safe or effective.
Evidence-informed overview
What to Expect
Evidence boundary
Research indications describe topics studied in the literature; they do not predict an individual outcome.
Clinical monitoring
Where an authorized medicinal use exists, expectations and monitoring should come from the current product label and treating clinician.
Risk overview
Side Effects & Safety
The safety profile of B7-33(Relaxin) cannot be inferred from category or molecular identity alone. Research-only materials are not medicines and should not be used in humans.
Verification
Quality Checklist
- Confirm exact chemical identity, sequence, salt form, and concentration.
- Require a batch-specific certificate of analysis with named test methods and results.
- Check manufacturer, lot, expiry, tamper evidence, and documented chain of custody.
- For laboratory work requiring sterility, verify sterility and endotoxin testing separately from purity.
Clear answers
Frequently Asked Questions
Is B7-33(Relaxin) approved for personal use?
This catalogue does not identify an authorized personal-use indication. Treat it as research information unless a current local regulator says otherwise.
Why is no dose listed?
A dose is shown only when it has been checked against a current authoritative prescribing label. Speculative or community regimens are intentionally excluded.
Do research indications prove effectiveness?
No. They organize literature topics and evidence signals; they are not treatment recommendations or guarantees.
Source trail
References
- A single-chain peptide derived from the relaxin B-chain selectively activates RXFP1Hossain, M.A., et al. · Chemical Science · 2016
- The single-chain relaxin mimetic, B7-33, maintains anti-fibrotic activity in liver and kidney fibrosis modelsHossain, M.A., et al. · British Journal of Pharmacology · 2020
- The relaxin receptor as a therapeutic target — perspectives from evolution and drug targetingBathgate, R.A.D., et al. · Pharmacology & Therapeutics · 2018
- B7-33 replicates the vasoprotective effects of relaxin in mouse models of cardiovascular diseaseMarshall, S.A., et al. · Annals of the New York Academy of Sciences · 2017
- The role of relaxin and its receptor (RXFP1) in the pathogenesis and treatment of fibrotic diseasesSamuel, C.S., et al. · Molecular and Cellular Endocrinology · 2017